Actions taken on HPV vaccine proposals in Alabama, Louisiana, Utah, Washington The following highlights recent news of state actions on human papillomavirus vaccine proposals . Merck’s HPV vaccine Gardasil and GlaxoSmithKline’s HPV vaccine Cervarix in scientific trials have been been shown to be 100 percent effective in preventing infections with HPV strains 16 and 18, which collectively trigger about 70 percent of cervical cancer cases. FDA in July 2006 accepted Gardasil for sale and marketing to women and women age groups nine to 26, and CDC’s Advisory Committee on Immunization Practices afterwards that month voted unanimously to advise that girls ages 11 and 12 have the vaccine.